GENENTECH, INC for GENENTECH INC
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 21, 2014 | $1,152,000 | Replaced |
| 1st Quarter - Amendment (this page) | Jul 14, 2014 | $926,490 | Yes |
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Proposed changes in global patent protections. Compulsory License Issues in India, trade related issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director |
| ELI KOGAN | Assistant Director |
Taxation/Internal Revenue Code TAX
Research and Development Tax credit,general tax issues and tax extenders (R&D tax credit) and tax treatment of foreign-owned US corporations; tax reform, Issues related to comprehensive tax reformand the tax treatment of foreign-owned U.S. corporations. S__, Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act (tax extenders), including the R&D tax credit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assistant Director |
| DARIN GARDNER | Director |
| ELI KOGAN | Assistant Director |
Copyright/Patent/Trademark CPT
Intellectual Property and Process Patent Issues - HR 1908 Patent Reform Act (all provisions, Cyber security, Transpacific partnership
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assistant Director |
| DARIN GARDNER | Director |
Health Issues HCR
S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act"; proposed cuts to Part B reimbursement. 340b reimbursement policy; MMM: Part B reimbursement; HCR: Issues related to the implementation of the Affordable Care Act of 2010, HCR: Issues relating to the treatment of biologics in international health programs, Reimbursement issues, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicar drug benefit.; Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act";Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; Issues relating to biologics
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assistant Director |
| DARIN GARDNER | Director |
| EVAN MORRIS | Vice President of Government Affairs |
| KATHERINE RAAB | Assistant Director |
Medicare/Medicaid MMM
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement, Public Law 11-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cance biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government ofr fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimbursement issues. Concerns regarding Medicare payment policies for Part B drugs. HCR: Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.Implementation of P.L. 108-173, matters related to Medi care and Medicaid Coverage and Reimbursement (Medicare Prescription Drug Act of 2003); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 942 - American Research and Competitiveness Act of 2011; Issues related to 340B; Medicare coverage and payment of Part B drugs and bilogicals.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assistant Director |
| DARIN GARDNER | Sr. Director |
| EVAN MORRIS | Vice President of Government Affairs |
| KATHERINE RAAB | Assistant Director |
Budget/Appropriations BUD
FY13 Labor, HHS and Education Appropriation related to preparedness for pandemic influenca, HIV/AIDS programs, hepatitis screening, care and treatment, and access t breast cancer treatment; Following issues related to the budget and appropriations process FY 13 appropriations for FDA as well as the potential outcomes for negotiations on altering sequestration targets via legislation, Issues related to FDA & HHS program funding, FY15 Labor Health and Human Services, and Education, and Related Agencies, and FY 15 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bills.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director |
| ELI KOGAN | Assistant Director |
| KATHERINE RAAB | Assistant Director |
Pharmacy PHA
Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies., Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program, structure of the Medicare presciption drug benefit. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010- Implementation issues related to Medicare and Medicaid reimbursement, fees assessd on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit. Public Law 112-144, the Food and Drug Administration Safety and Innovation Act - legislation related to reauthorization of user fees for prescription drug, medical device, and bilogics approval. All aspects. General issues and congressional oversight related to FDA approval and CMS coverage decisions regarding Avastin and Lucentis. S. 959 - Pharmaceutical Quality, Security, and Accountability Act- legislation regardng pharmacy compounding and track and trace proposals. Public Law 113-67, Continuing Appropriations Resolution for 2014 - General public health spending.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assistant Director |
| ELI KOGAN | Assistant Director |
| KATHERINE RAAB | Assistant Director |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.